Maverix Medical Closes Acquisition Of Cirrus Bio As Foundation For Diagnostics Platform In Lung Cancer
Maverix Medical, a pioneering platform dedicated to combating lung cancer, forged through collaboration between Ajax Health, KKR, and Hologic, Inc., has announced a significant milestone with the acquisition of Cirrus Bio. This strategic move underscores Maverix Medical's commitment to advancing diagnostic capabilities in the fight against lung cancer.
Cirrus Bio is renowned for its development and commercialization of multiomic solutions crucial for early disease diagnosis and management. Led by industry veterans David Mallery (CEO) and Scott Morris (CSO), Cirrus Bio brings a wealth of experience from founding and leading successful ventures in the healthcare sector, including the Molecular Profiling Institute, Paradigm Diagnostics, Viomics, and the International Genomics Consortium.
The acquisition of Cirrus Bio marks the inception of Maverix Dx, a specialized diagnostic division within Maverix Medical. Maverix Dx will focus on developing, investing in, acquiring, and commercializing state-of-the-art diagnostic tools tailored for lung cancer diagnosis and management. David Mallery will assume the role of Chief Executive Officer, while Scott Morris will serve as Chief Scientific Officer, leveraging their expertise to drive innovation within the division.
Duke Rohlen, Executive Chairman of Maverix Medical, underscored the importance of early detection in improving lung cancer outcomes, citing it as the primary driver behind the acquisition. With Cirrus Bio's advanced technology and experienced team, Maverix Medical aims to revolutionize lung cancer care by offering a comprehensive suite of diagnostic solutions.
In addition to the Cirrus Bio acquisition, Maverix Medical also introduced Serpex Medical, a groundbreaking product platform focusing on steerable technologies for precise lung tissue biopsy and therapy delivery. Led by Serpex founder and CEO Sasha Schrode, Serpex Medical will form the core of Maverix's medical device division, Maverix Med Device.
David Mallery, CEO of Maverix Dx, expressed confidence in the potential of the lung cancer market, highlighting opportunities for innovation and collaboration. Backed by financial sponsors KKR and Hologic, Maverix Medical remains committed to investing in both developmental and commercial-stage lung cancer companies, seeking partnerships to drive advancements in lung cancer care.

Comments
Post a Comment